Litchfield Hills Starts NextPlat (NXPL) at Buy

Litchfield Hills analyst Theodore O'Neill initiates coverage on NextPlat (NASDAQ: NXPL) with a Buy rating and a price target of $11.00.

The analyst commented: "Initiating coverage of NextPlat Corp, with a Buy rating and $11 PT. In the healthcare segment, an aging population offers a double benefit for NXPL: older people generally require more medication, and the number of large retail pharmacy chains is shrinking. Nationwide expansion grows TAM. In March 2026, NextPlat announced it is expanding beyond Florida through a nationwide online fulfillment partnership, which is expected to significantly expand the Company's addressable market. Focused on higher margin healthcare opportunities. The company is moving from an all-around provider of retail healthcare services to include a greater focus on higher margin, contracted healthcare services opportunities for 340B entities and long-term care facilities, where it is gaining market share. Increased awareness and availability of satellite communications driving demand. In the e-Commerce segment, a growing number of people and many public and private institutions are increasingly aware that they need reliable secure communications that don’t have to depend on an available cell tower. Measurable financial improvements underway. The company just reported 1Q26 where its strategy showed measurable improvements in margins, operating efficiency and overall financial performance. This follows a change in CEO in early 2025 and a subsequent restructuring. Attractive valuation. The shares sell at a discount to our discounted earnings driven price target and to their peers. On the healthcare side, the shares sell at a 79% discount to peer averages for Pharmacy/Pharmacy Benefit Managers. On the communication side, the shares are at a >95% discount to peer averages."

For an analyst ratings summary and ratings history on NextPlat click here. For more ratings news on NextPlat click here.

Shares of NextPlat closed at $6.35 yesterday.

You May Also Be Interested In

• Bending Spoons (BSP) PT Raised to $50 at Benchmark on Inaugural Earnings, Revenue Beat
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Boost Run posts Q2 revenue of $31.1M, up 270% year over year